GANNET53
A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer
| Coordinatore | MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
| Nazionalità Coordinatore | Austria [AT] |
| Sito del progetto | http://www.gannet53.eu/ |
| Totale costo | 7˙777˙447 € |
| EC contributo | 5˙994˙072 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2019-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | coordinator | 1˙564˙140.00 |
| 2 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 700˙011.00 |
| 3 |
ONCOLAB DIAGNOSTICS GMBH
Organization address
address: VIKTOR KAPLAN STRASSE 2 contact info |
AT (WIENER NEUSTADT) | participant | 549˙944.00 |
| 4 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 465˙989.00 |
| 5 |
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Organization address
address: Robert-Koch-Strasse 40 contact info |
DE (GOETTINGEN) | participant | 371˙778.00 |
| 6 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 371˙489.00 |
| 7 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 287˙250.00 |
| 8 |
AGO RESEARCH GMBH
Organization address
address: KAISER-FRIEDRICH RING 71 contact info |
DE (WIESBADEN) | participant | 198˙562.00 |
| 9 |
CENTRE ANTICANCEREUX LEON BERARD
Organization address
address: RUE LAENNEC 28 contact info |
FR (LYON) | participant | 197˙715.00 |
| 10 |
ARCAGY ASSOCIATION
Organization address
address: PLACE DU PARVIS NOTRE DAME 1 contact info |
FR (PARIS) | participant | 180˙562.00 |
| 11 |
XAILABS GMBH
Organization address
address: LOBECKSTRASSE 36 contact info |
DE (BERLIN) | participant | 180˙474.00 |
| 12 |
Nome Ente NON disponibile
Organization address
address: Domstrasse 11 contact info |
DE (GREIFSWALD) | participant | 170˙670.00 |
| 13 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | participant | 161˙655.00 |
| 14 |
KLINIKEN ESSEN-MITTE EVANG. HUYSSENS-STIFTUNG/KNAPPSCHAFT GEMEINNUTZIGE GMBH
Organization address
address: HENRICISTRASSE 92 contact info |
DE (ESSEN) | participant | 143˙625.00 |
| 15 |
NORD-OSTDEUTSCHE GESELLSCHAFT FUR GYNAKOLOGISCHE ONKOLOGIE EV
Organization address
address: AUGUSTENBURGER PLATZ 1 contact info |
DE (BERLIN) | participant | 136˙528.00 |
| 16 |
CENTRE REGIONAL FRANCOIS BACLESSE
Organization address
address: avenue du general Harris 3 contact info |
FR (CAEN CEDEX 5) | participant | 125˙595.00 |
| 17 |
TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE 10 contact info |
DE (DRESDEN) | participant | 98˙550.00 |
| 18 |
OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG
Organization address
address: UNIVERSITAETSPLATZ 2 contact info |
DE (MAGDEBURG) | participant | 89˙535.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Epithelial ovarian cancer (EOC) is the most lethal gyncaecological malignancy causing 41900 deaths annually in Europe. The predominance of aggressive Type II tumours, which are characterised by a high frequency of p53 mutations, and primary or acquired resistance to platinum-based chemotherapy profoundly contribute to the high mortality rate. With current standard therapy the median overall survival of metastatic platinum-resistant (Pt-R) ovarian cancer patients is only 14 month. There is a pressing need for more effective, innovative treatment strategies to particularly improve survival in this subgroup of EOC patients. The GANNET53 trial aims to achieve this goal by applying a highly innovative concept that has grown from solid basic research findings made by members of the GANNET53 consortium. This is a drug strategy targeting a central driver of tumour aggressiveness and metastatic ability, namely mutant p53, via an innovative new Hsp90 (heat shock protein 90) inhibition mechanism. The most advanced, second-generation Hsp90 inhibitor will be used, Ganetespib. The first part (Phase I) of the GANNET53 trial will test the safety of Ganetespib in a new combination with standard chemotherapy (Paclitaxel weekly) in Pt-R Type II EOC patients. The second part (randomised Phase II) will examine the efficacy of Ganetespib in combination with standard chemotherapy versus standard chemotherapy alone in EOC patients with Pt-R Type II tumours. We established a highly efficient consortium with previously proven capability and manpower to perform this multicentre clinical trial and assess our innovative therapeutic concept in this deadly disease. Our consortium consists of national clinical trial groups in gynaecological oncology and high-volume University centres as well as noted p53 scientists and 3 innovative SMEs. Since ovarian cancer is defined as a rare cancer a scale at the European level is crucial for the planned clinical trial.'